TARA-002

Phase 3Biologic

PProtara Therapeutics

TARA-002 is one of 48 biologic programs targeting Lymphatic Malformation. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphatic MalformationActive, not recruiting

Bladder CancerActive, not recruiting

Non Muscle Invasive Bladder CancerRecruiting

Bladder (urothelial, Transitional Cell) CancerRecruiting

Lymphatic MalformationPhase 2

Active, not recruiting

Bladder CancerPhase 3

Active, not recruiting

Non Muscle Invasive Bladder CancerPhase 2

Recruiting

Bladder (urothelial, Transitional Cell) CancerPhase 3

Recruiting

Competition

Competitive Landscape

378 competitors in Bladder Cancer

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

61 2

Trexall

Alnylam Pharmaceuticals

Phase 3

13 3

Velban

Eli Lilly

Phase 3

8 4

Adriamycin

Pfizer

Phase 3

6 5

Entereg

Merck & Co.

Phase 3

1 6

Mitosol

UUroGen Pharma Ltd.

Phase 3

9 7

Paraplatin

AAvyxa

Phase 3

9 8

Mitomycin C

GGynecologic Oncology Group

Phase 3

16 9

Bacillus Calmette-Guérin

Bristol-Myers Squibb

Phase 3

4 10

Sacituzumab Tirumotecan

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 2Recruiting

Non Muscle Invasive Bladder Cancer

NCT05951179

Q4 2032

Phase 3Recruiting

Bladder (urothelial, Transitional Cell) Cancer

NCT07480356

Clinical

Trials by Indication[1]

Bladder Cancer2 trials

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

Completed·PProtara Therapeutics·Phase 1·NCT05085977·12 enrolled

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)

Completed·PProtara Therapeutics·Phase 1·NCT05085990·10 enrolled

Lymphatic Malformation1 trial

Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

Recruiting·PProtara Therapeutics·Phase 2·NCT05871970·38 enrolled

Non Muscle Invasive Bladder Cancer1 trial

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer

Recruiting·PProtara Therapeutics·Phase 2·NCT05951179·131 enrolled

Bladder (Urothelial, Transitional Cell) Cancer1 trial

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-Grade Non-Muscle Invasive Bladder Cancer

Recruiting·PProtara Therapeutics·Phase 3·NCT07480356·284 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for TARA-002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TARA-002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TARA-002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Protara Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: PProtara Therapeutics

TARA-002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Q4 2032

Trials by Indication[1]

Bladder Cancer2 trials

Lymphatic Malformation1 trial

Non Muscle Invasive Bladder Cancer1 trial

Bladder (Urothelial, Transitional Cell) Cancer1 trial

References

Drug Info

Quick Facts

Related News